Is Shopify Stock a Good Buy Now?
eCommerce technology platform Shopify (NASDAQ:SHOP) delivered impressive returns in 2025…
Sell
50
NWBO Quote, Financials, Valuation and Earnings
Last price:
$0.26
Seasonality move
:
42.2%
Day range:
$0.25 - $0.27
52-week range:
$0.17 - $0.48
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
390.65x
P/B ratio:
--
Volume:
3.6M
Avg. volume:
3.9M
1-year change:
-1.54%
Market cap:
$404.4M
Revenue:
$1.4M
EPS (TTM):
-$0.07
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NWBO
Northwest Biotherapeutics, Inc.
|
-- | -- | -- | -- | -- |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
NanoViricides, Inc.
|
-- | -$0.08 | -- | -42.49% | $6.50 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.37 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NWBO
Northwest Biotherapeutics, Inc.
|
$0.26 | -- | $404.4M | -- | $0.00 | 0% | 390.65x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$19.16 | $0.85 | $2.4B | 32.19x | $0.80 | 0% | 37.23x |
|
NNVC
NanoViricides, Inc.
|
$1.12 | $6.50 | $20.2M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics, Inc.
|
$0.83 | $2.00 | $683.9K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.21 | $7.00 | $7.2M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NWBO
Northwest Biotherapeutics, Inc.
|
-425.16% | 0.083 | 20.38% | 0.05x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | -3.190 | 8.08% | 1.85x |
|
NNVC
NanoViricides, Inc.
|
-- | 0.780 | -- | 0.95x |
|
OGEN
Oragenics, Inc.
|
3.86% | 0.905 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -2.522 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NWBO
Northwest Biotherapeutics, Inc.
|
-$321K | -$14.3M | -- | -- | -7160% | -$14.1M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
NNVC
NanoViricides, Inc.
|
-$132.8K | -$1.8M | -92.29% | -92.29% | -- | -$1.7M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
Northwest Biotherapeutics, Inc. vs. Competitors
-
Which has Higher Returns NWBO or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -13414.5% compared to Northwest Biotherapeutics, Inc.'s net margin of -255.85%. Northwest Biotherapeutics, Inc.'s return on equity of -- beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital NWBONorthwest Biotherapeutics, Inc.-160.5% -$0.02 -$18.1M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About NWBO or NBY?
Northwest Biotherapeutics, Inc. has a consensus price target of --, signalling upside risk potential of 2947.62%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -95.56%. Given that Northwest Biotherapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Northwest Biotherapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NWBONorthwest Biotherapeutics, Inc.0 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is NWBO or NBY More Risky?
Northwest Biotherapeutics, Inc. has a beta of -0.861, which suggesting that the stock is 186.058% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.093, suggesting its less volatile than the S&P 500 by 90.725%.
-
Which is a Better Dividend Stock NWBO or NBY?
Northwest Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Northwest Biotherapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NWBO or NBY?
Northwest Biotherapeutics, Inc. quarterly revenues are $200K, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Northwest Biotherapeutics, Inc.'s net income of -$26.8M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Northwest Biotherapeutics, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 32.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Northwest Biotherapeutics, Inc. is 390.65x versus 37.23x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NWBONorthwest Biotherapeutics, Inc.390.65x -- $200K -$26.8M NBYNovaBay Pharmaceuticals, Inc.37.23x 32.19x $521K -$1.3M
-
Which has Higher Returns NWBO or NNVC?
NanoViricides, Inc. has a net margin of -13414.5% compared to Northwest Biotherapeutics, Inc.'s net margin of --. Northwest Biotherapeutics, Inc.'s return on equity of -- beat NanoViricides, Inc.'s return on equity of -92.29%.
Company Gross Margin Earnings Per Share Invested Capital NWBONorthwest Biotherapeutics, Inc.-160.5% -$0.02 -$18.1M NNVCNanoViricides, Inc.-- -$0.10 $7.2M -
What do Analysts Say About NWBO or NNVC?
Northwest Biotherapeutics, Inc. has a consensus price target of --, signalling upside risk potential of 2947.62%. On the other hand NanoViricides, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 480.36%. Given that Northwest Biotherapeutics, Inc. has higher upside potential than NanoViricides, Inc., analysts believe Northwest Biotherapeutics, Inc. is more attractive than NanoViricides, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NWBONorthwest Biotherapeutics, Inc.0 0 0 NNVCNanoViricides, Inc.1 0 0 -
Is NWBO or NNVC More Risky?
Northwest Biotherapeutics, Inc. has a beta of -0.861, which suggesting that the stock is 186.058% less volatile than S&P 500. In comparison NanoViricides, Inc. has a beta of 1.234, suggesting its more volatile than the S&P 500 by 23.439%.
-
Which is a Better Dividend Stock NWBO or NNVC?
Northwest Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoViricides, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Northwest Biotherapeutics, Inc. pays -- of its earnings as a dividend. NanoViricides, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NWBO or NNVC?
Northwest Biotherapeutics, Inc. quarterly revenues are $200K, which are larger than NanoViricides, Inc. quarterly revenues of --. Northwest Biotherapeutics, Inc.'s net income of -$26.8M is lower than NanoViricides, Inc.'s net income of -$1.8M. Notably, Northwest Biotherapeutics, Inc.'s price-to-earnings ratio is -- while NanoViricides, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Northwest Biotherapeutics, Inc. is 390.65x versus -- for NanoViricides, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NWBONorthwest Biotherapeutics, Inc.390.65x -- $200K -$26.8M NNVCNanoViricides, Inc.-- -- -- -$1.8M
-
Which has Higher Returns NWBO or OGEN?
Oragenics, Inc. has a net margin of -13414.5% compared to Northwest Biotherapeutics, Inc.'s net margin of --. Northwest Biotherapeutics, Inc.'s return on equity of -- beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital NWBONorthwest Biotherapeutics, Inc.-160.5% -$0.02 -$18.1M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About NWBO or OGEN?
Northwest Biotherapeutics, Inc. has a consensus price target of --, signalling upside risk potential of 2947.62%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 140.65%. Given that Northwest Biotherapeutics, Inc. has higher upside potential than Oragenics, Inc., analysts believe Northwest Biotherapeutics, Inc. is more attractive than Oragenics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NWBONorthwest Biotherapeutics, Inc.0 0 0 OGENOragenics, Inc.1 0 0 -
Is NWBO or OGEN More Risky?
Northwest Biotherapeutics, Inc. has a beta of -0.861, which suggesting that the stock is 186.058% less volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.903, suggesting its less volatile than the S&P 500 by 9.685%.
-
Which is a Better Dividend Stock NWBO or OGEN?
Northwest Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Northwest Biotherapeutics, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NWBO or OGEN?
Northwest Biotherapeutics, Inc. quarterly revenues are $200K, which are larger than Oragenics, Inc. quarterly revenues of --. Northwest Biotherapeutics, Inc.'s net income of -$26.8M is lower than Oragenics, Inc.'s net income of -$3.1M. Notably, Northwest Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Northwest Biotherapeutics, Inc. is 390.65x versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NWBONorthwest Biotherapeutics, Inc.390.65x -- $200K -$26.8M OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns NWBO or PTN?
Palatin Technologies has a net margin of -13414.5% compared to Northwest Biotherapeutics, Inc.'s net margin of --. Northwest Biotherapeutics, Inc.'s return on equity of -- beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NWBONorthwest Biotherapeutics, Inc.-160.5% -$0.02 -$18.1M PTNPalatin Technologies-- -- -- -
What do Analysts Say About NWBO or PTN?
Northwest Biotherapeutics, Inc. has a consensus price target of --, signalling upside risk potential of 2947.62%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Northwest Biotherapeutics, Inc., analysts believe Palatin Technologies is more attractive than Northwest Biotherapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NWBONorthwest Biotherapeutics, Inc.0 0 0 PTNPalatin Technologies0 0 0 -
Is NWBO or PTN More Risky?
Northwest Biotherapeutics, Inc. has a beta of -0.861, which suggesting that the stock is 186.058% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock NWBO or PTN?
Northwest Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Northwest Biotherapeutics, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NWBO or PTN?
Northwest Biotherapeutics, Inc. quarterly revenues are $200K, which are larger than Palatin Technologies quarterly revenues of --. Northwest Biotherapeutics, Inc.'s net income of -$26.8M is higher than Palatin Technologies's net income of --. Notably, Northwest Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Northwest Biotherapeutics, Inc. is 390.65x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NWBONorthwest Biotherapeutics, Inc.390.65x -- $200K -$26.8M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns NWBO or TOVX?
Theriva Biologics, Inc. has a net margin of -13414.5% compared to Northwest Biotherapeutics, Inc.'s net margin of --. Northwest Biotherapeutics, Inc.'s return on equity of -- beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital NWBONorthwest Biotherapeutics, Inc.-160.5% -$0.02 -$18.1M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About NWBO or TOVX?
Northwest Biotherapeutics, Inc. has a consensus price target of --, signalling upside risk potential of 2947.62%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3158.85%. Given that Theriva Biologics, Inc. has higher upside potential than Northwest Biotherapeutics, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Northwest Biotherapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NWBONorthwest Biotherapeutics, Inc.0 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is NWBO or TOVX More Risky?
Northwest Biotherapeutics, Inc. has a beta of -0.861, which suggesting that the stock is 186.058% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.343, suggesting its less volatile than the S&P 500 by 65.729%.
-
Which is a Better Dividend Stock NWBO or TOVX?
Northwest Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Northwest Biotherapeutics, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NWBO or TOVX?
Northwest Biotherapeutics, Inc. quarterly revenues are $200K, which are larger than Theriva Biologics, Inc. quarterly revenues of --. Northwest Biotherapeutics, Inc.'s net income of -$26.8M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Northwest Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Northwest Biotherapeutics, Inc. is 390.65x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NWBONorthwest Biotherapeutics, Inc.390.65x -- $200K -$26.8M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Why Did Planet Labs Stock Rally So Much?
Satellite imaging startup Planet Labs (NYSE:PL), after years of disappointing…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
71
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
Buy
54
LGIH alert for Jan 10
LGI Homes, Inc. [LGIH] is up 13.81% over the past day.
